| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/18/2000 | US6015695 Immunoglobulins devoid of light chains |
| 01/18/2000 | US6015688 Transferrin receptor genes |
| 01/18/2000 | US6015678 Method for detection of a polynucleotide encoding protein kinase C inhibitor-homolog |
| 01/18/2000 | US6015578 Trapidil for use in the therapy of syndrome that may be influenced by immunomodulators |
| 01/18/2000 | US6015564 Polypeptides with fatty acid and steroids |
| 01/18/2000 | US6015563 Polyphosphazene polyelectrolyte immunoadjuvants |
| 01/18/2000 | US6015559 Fas antagonists |
| 01/18/2000 | CA2172472C Pyrido[3,2-e]pyrazinones with anti-asthmatic action and processes for their manufacture |
| 01/18/2000 | CA2000985C 1,4-diazepine derivative and its pharmaceutical use |
| 01/13/2000 | WO2000001821A2 Neurotransmission associated proteins |
| 01/13/2000 | WO2000001818A1 Human emr1-like g protein coupled receptor |
| 01/13/2000 | WO2000001815A2 Neurotrophic factors |
| 01/13/2000 | WO2000001728A1 Galectin 11 |
| 01/13/2000 | WO2000001716A2 Vasculoprotector |
| 01/13/2000 | WO2000001715A1 Novel cyclosporin with improved activity profile |
| 01/13/2000 | WO2000001690A1 Cinnamic acid derivatives as cell adhesion molecules |
| 01/13/2000 | WO2000001676A1 Potassium channel blocking agents |
| 01/13/2000 | WO2000001671A2 Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
| 01/13/2000 | WO2000001670A1 Substituted nitrogen and sulfur alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | WO2000001666A1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 01/13/2000 | WO2000001414A1 Use of texaphyrins in macrophage-mediated disease |
| 01/13/2000 | WO2000001409A2 Porcine circovirus and parvovirus vaccine |
| 01/13/2000 | WO2000001395A1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/13/2000 | WO2000001386A1 Farnesyl protein transferase inhibitors for treating arthropathies |
| 01/13/2000 | WO2000001381A1 Substituted oxygen alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | WO2000001349A2 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| 01/13/2000 | WO2000001345A2 Use of an amphipathic compound for providing an adjuvant to a subunit vaccine |
| 01/13/2000 | WO1999060135A8 Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases |
| 01/13/2000 | WO1999059617A3 Immunoregulator |
| 01/13/2000 | WO1999055312A3 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 01/13/2000 | WO1999053047A3 Porcine adenovirus type 3 genome |
| 01/13/2000 | WO1999051259A3 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/13/2000 | WO1999046367A8 Methods of diagnosis and triage using cell activation measures |
| 01/13/2000 | CA2402839A1 Galectin 11 |
| 01/13/2000 | CA2356841A1 Substituted nitrogen and sulfur alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | CA2345919A1 Substituted oxygen alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | CA2337048A1 Use of an amphipathic compound for providing an adjuvant to a subunit vaccine |
| 01/13/2000 | CA2336406A1 Galectin 11 |
| 01/13/2000 | CA2336134A1 Use of texaphyrins in macrophage-mediated disease |
| 01/13/2000 | CA2335920A1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/13/2000 | CA2332309A1 Neurotransmission associated proteins |
| 01/13/2000 | CA2331394A1 Human emr1-like g protein coupled receptor |
| 01/12/2000 | EP0970950A2 Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
| 01/12/2000 | EP0970226A1 Vectors having enhanced expression, and methods of making and uses thereof |
| 01/12/2000 | EP0970215A1 Suppressor of cytokine signaling |
| 01/12/2000 | EP0970213A2 Death domain containing receptor 5 |
| 01/12/2000 | EP0970186A1 SpoOJ2 OF STAPHYLOCOCCUS AUREUS |
| 01/12/2000 | EP0970128A1 Immunotherapeutic ctla-4 binding peptides |
| 01/12/2000 | EP0970127A1 Antibody variants |
| 01/12/2000 | EP0970126A2 Method for the production of antihuman antigen receptors and uses thereof |
| 01/12/2000 | EP0970114A1 Neoglycoproteins |
| 01/12/2000 | EP0970111A2 Secreted proteins and polynucleotides encoding them |
| 01/12/2000 | EP0970108A2 Secreted proteins and polynucleotides encoding them |
| 01/12/2000 | EP0970084A1 Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
| 01/12/2000 | EP0970081A1 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders |
| 01/12/2000 | EP0970076A1 7-[(piperidin-1-yl)- propoxy]-chromen-4-one derivatives, their preparation and their pharmaceutical use |
| 01/12/2000 | EP0970056A1 Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
| 01/12/2000 | EP0970046A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 01/12/2000 | EP0970036A1 Aryl- and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
| 01/12/2000 | EP0969872A2 Induction of b cell tolerance |
| 01/12/2000 | EP0969867A2 Use of anti-il-12 antibodies in transplantation rejection |
| 01/12/2000 | EP0969865A1 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| 01/12/2000 | EP0969864A1 Hiv p-17 peptide fragment, compositions containing and methods for producing and using same |
| 01/12/2000 | EP0969862A2 SYNTHETIC HIV $i(GAG) GENES |
| 01/12/2000 | EP0969859A1 The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf) |
| 01/12/2000 | EP0969857A1 Pharmaceutical compositions |
| 01/12/2000 | EP0969856A1 Hydrophilic binary systems for the administration of cyclosporine |
| 01/12/2000 | EP0969842A1 Pharmaceutical composition |
| 01/12/2000 | EP0969836A1 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 01/12/2000 | EP0969833A1 Extension of the expression of transgenic proteins by immunomodulation |
| 01/12/2000 | EP0969829A1 Synthetic techniques and intermediates for polyhydroxy, dienyllactones and mimics thereof |
| 01/12/2000 | EP0969817A1 Dosage forms having improved release properties |
| 01/12/2000 | EP0969815A2 Pharmaceutical compositions |
| 01/12/2000 | EP0862566B1 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives |
| 01/12/2000 | EP0722341B1 Non-ionic surfarctant vesicles comprising antigens |
| 01/12/2000 | EP0639079B1 Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 01/12/2000 | EP0594764B1 Hematopoietic growth factor derived from t lymphocytes and methods of use therefor |
| 01/12/2000 | CN1048241C Vitamin D analogues, their preparing process, pharmaceutical composition contg. same and use thereof |
| 01/11/2000 | US6013814 Vitamin D analogues |
| 01/11/2000 | US6013781 Semaphorin gene family |
| 01/11/2000 | US6013765 Cell surface peptides that can be used as antitumor agents |
| 01/11/2000 | US6013648 Immunomodulators |
| 01/11/2000 | US6013641 Inhibiting lymphocytes |
| 01/11/2000 | US6013627 Organic compounds |
| 01/11/2000 | US6013487 Chimeric RNA molecules generated by trans-splicing |
| 01/11/2000 | US6013480 Antagonists of interleukin-15 |
| 01/11/2000 | US6013479 Human Emr1-like G protein coupled receptor |
| 01/11/2000 | US6013476 DNA encoding tumor necrosis related receptor TR7 |
| 01/11/2000 | US6013464 Human PAK65 |
| 01/11/2000 | US6013455 Polynucleotides which identify and encode protein kinase homologs, amino acid sequences encoding pkh; methods of pkh production with expression vectors; hybridizes under given conditions |
| 01/11/2000 | US6013454 Kinesin-like motor protein |
| 01/11/2000 | US6013258 Immunogenic peptides from the HPV E7 protein |
| 01/11/2000 | US6013256 Administering to human patients undergoing renal transplants effective dosage of chimeric or humanized monoclonal antibody that binds to p55 subunit of human interleukin-2 (il-2) receptor and inhibits binding of il-2 to an il-2 receptor |
| 01/07/2000 | CA2276791A1 Use of adenoviral e4 reading frames to improve expression of a gene of interest |
| 01/06/2000 | WO2000000825A2 Detection and modulation of cellular immunity to immune privileged antigens |
| 01/06/2000 | WO2000000609A2 Molecules associated with apoptosis |
| 01/06/2000 | WO2000000608A2 Immune system molecules |
| 01/06/2000 | WO2000000599A2 Composition for the induction of apoptosis in target cells |
| 01/06/2000 | WO2000000596A1 3'-exonuclease, production and use thereof |
| 01/06/2000 | WO2000000594A2 Human transferases |